Skip to search formSkip to main contentSkip to account menu

fevipiprant

Known as: 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Indoleacetic AcidsPyridines

Narrower (1)

NVP-QAW039

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach
This drug-drug interaction study determined the effect of cyclosporine, an inhibitor of organic anion transporting polypeptide… 
2019
2019
Long-Term Safety of Fevipiprant (QAW039) in Patients with Asthma, Inadequately Controlled on Standard-of-Care Therapy: Design of The Phase III SPIRIT Trial
2019
2019
Beyond T2-inflammation: What Does the Future Hold for Severe Asthma?
Asthma is a common inflammatory airways disease affecting over 300 million people. It is considered severe in 5-10% of cases… 
2018
2018
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
Review
2017
Review
2017
Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses
Introduction: Fevipiprant, an oral prostaglandin D2 receptor 2 (DP2/CRTh2) antagonist, is in clinical development for treatment… 
2017
2017
Clinically-relevant computational model of airway remodelling to design and optimise interventions to treat asthma
Introduction: Quantifying the mechanisms underpinning asthma requires computational models that offer tightly controlled… 
2017
2017
ERJ August Podcast: Fevipiprant in allergic asthma not controlled by low-dose inhaled corticosteroids
As part of the August issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc… 
2016
2016
Impact of co-administration of fevipiprant (QAW039) and SLCO1B1 genotype on the PK of simvastatin and rosuvastatin
Rationale Fevipiprant, an oral CRTh2 antagonist, inhibited OATP1B1, OATP1B3 and OATP2B1 in vitro. The [I]/Ki ratios indicated a… 
2016
2016
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Introduction We assessed the dose-related efficacy and safety of fevipiprant, an oral CRTh2 antagonist, in patients with atopic… 
2016
2016
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)